Cas:1108656-90-1 4-methylbenzenesulfonic acid,N-methylhex-5-en-1-amine manufacturer & supplier

Chemical Name:4-methylbenzenesulfonic acid,N-methylhex-5-en-1-amine

CAS.NO:1108656-90-1

Synonyms:N-methylhex-5-en-1-amine 4-methylbenzenesulfonate;N-methylhex-5-en-1-amine tosylate salt;5-Hexen-1-amine, N-methyl-, 4-methylbenzenesulfonate (1:1);N-methylhex-5-en-1-amine 4-methylbenzenesulfonate (1:1);N-Methyl-5-hexen-1-amine 4-methylbenzenesulfonate (1:1)

Molecular Formula:C₁₄H₂₃NO₃S

Molecular Weight:285.402

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:74.78000

Exact Mass:285.139862

LogP:4.27550

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-methylhex-5-en-1-amine 4-methylbenzenesulfonate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Methyl-5-hexen-1-amine 4-methylbenzenesulfonate (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-methylhex-5-en-1-amine 4-methylbenzenesulfonate Use and application,N-methylhex-5-en-1-amine 4-methylbenzenesulfonate (1:1) technical grade,usp/ep/jp grade.

Related News: As for the consumer health unit, GSK plans to demerge it by mid-2022, during which GSK will shed at least 80% of its 68% holding in the JV to shareholders. (2S,5S,6R)-2-(tert-butyl)-5-hexyl-6-((1S)-1-hydroxy-2-nitrotridecyl)-1,3-dioxan-4-one manufacturers Many specialty and biotech organizations are now relying on external service providers to minimize the costs of manufacturing and in-house development required to develop molecules for new drugs and their subsequent clinical trials, explains Saurabh Gurnurkar, executive director, UQUIFA. magnesium,zinc (1:1) suppliers By integrating biocatalysis into ongoing and newly launched projects, Wavelength Pharmaceuticals has shown that it is possible to reduce overall costs by as much as 30%. molybdenum,osmium vendor & factory Altogether, the IPO added $550 million to the family’s collective fortune, which now stands at an estimated $4.8 billion. ,Many specialty and biotech organizations are now relying on external service providers to minimize the costs of manufacturing and in-house development required to develop molecules for new drugs and their subsequent clinical trials, explains Saurabh Gurnurkar, executive director, UQUIFA.